<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00877604</url>
  </required_header>
  <id_info>
    <org_study_id>TUDCA200701</org_study_id>
    <secondary_id>EudraCT No.: 2007-001592-10</secondary_id>
    <nct_id>NCT00877604</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerability of Tauroursodeoxycholic Acid in Amyotrophic Lateral Sclerosis</brief_title>
  <acronym>TUDCA-ALS</acronym>
  <official_title>A Randomized, Double-blind Multicenter Pilot Study vs. Placebo for the Evaluation of Efficacy and Tolerability of Tauroursodeoxycholic Acid Administered by Oral Route as Add on Treatment in Patients Affected by Amyotrophic Lateral Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Palermo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Federico II University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The preclinical rationale for tauroursodeoxycholic acid (TUDCA) use in treating patients with
      amyotrophic lateral sclerosis (ALS) stems from the demonstration of antioxidant,
      antiapoptotic and neuroprotective properties of TUDCA in the central nervous system (CNS),
      both in vitro and in vivo models.

      This protocol is meant for assessing if the addition of TUDCA to the conventional therapy can
      improve the therapeutic outcome in patients affected by ALS.

      Safety will be assessed for all subjects, for the entire duration of the study. 30 patients
      affected by ALS with site of onset in the limbs will be recruited.

      All enrolled subjects will continue receiving riluzole at the same regimen as before entering
      the trial. Based on an appropriate random code, subjects will be divided into two groups of
      equal size treated, after a lead-in period of 3 months, by oral route with TUDCA at the dose
      2 g daily for 1 year or with identical placebo by oral route at the same dosing schedule,
      under double-blind conditions.

      Every concomitant and/or supportive therapy will be admitted.

      Evaluation criteria:

      Efficacy. The proportion of responder patients in the two treatment groups was the primary
      outcome measure of the study. Responder patients were defined as those subjects showing an
      improvement of at least 15% in the ALSFRS-R (2) slope during the treatment period as compared
      to the lead-in period. This threshold was chosen based according to the consensus conference
      on designing and implementing clinical trials in ALS (3).

      Other parameters will include ALSFRS-R at study end, FVC%, the SF-36 quality of life rating
      scale, time to tracheotomy from starting of study medication dosing (if appropriate),
      survival Time from starting of study medication dosing (if appropriate), Medical Research
      Council scores for right and left muscle groups.

      Safety. Incidence, severity and type of adverse events; changes in clinical laboratory
      findings.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Amyotrophic lateral sclerosis (ALS), or motor neuron disease (MND), is a rapidly progressive,
      fatal neurodegenerative condition characterized by loss of upper and lower motor neurons in
      the brain and spinal cord. The terms ALS and MND are often used inter-changeably to cover the
      different clinical syndromes, which include upper and lower motor neuron disorder,
      progressive bulbar palsy, and pseudo-polyneuritic form.

      Degeneration of lower motor neurons (LMN) in the anterior horns of spinal cord and brainstem
      leads to progressive muscular atrophy and eventually to death within a few years due to
      respiratory insufficiency. During the course of the disease, the involvement of tongue and
      pharynx muscles causes swallowing impairment with marked drooling, need of parenteral or
      enteral feeding, and finally gastrostomy. Denervation of laryngeal muscles causes loss of
      speech. Cramps and fasciculation typically occur from the early phases of the disease.
      Degeneration of upper motor neurons (UMN) in the brain cortex causes pyramidal tract
      dysfunctions including clonus, Babinski sign, hypertonia, and loss of dexterity that further
      limit patients' daily activities.

      The incidence of ALS varies from 0.2 to 2.5 cases per 100,000 per year, although estimates
      vary between countries, likely reflecting a combination of availability of medical services,
      diagnostic accuracy, and demo-graphic characteristics of the area. Increasing life expectancy
      and improvements in standards of treatment and care will also result in an increased
      incidence of ALS. Globally, the overall rate is approximately 2 per 100,000. Its prevalence
      is approximately of 7 per 100,000. In Italy, the reported incidence of ALS is 2.2
      cases/100,000/year.

      There is currently no cure for ALS. Despite initial positive results in preclinical and early
      clinical studies, large-scale clinical trials with all agents except riluzole failed to
      demonstrate a clinically meaningful therapeutic effect in patients with ALS. Riluzole at the
      dose of 100 mg/day showed a significant difference on survival (6.4%; gain of 3 months) and
      slowed deterioration in muscle strength.

      Primary involvement of apoptotic mechanisms has important implications in selecting drug
      candidates for therapy in ALS. Recent preclinical studies have demonstrated that TUCA is
      endowed with antioxidant, antiapoptotic and neuroprotective activities. In particular, TUDCA
      can cross the blood-brain-barrier and has been shown to exert a significant therapeutic
      effect in a model of HD mice.

      Tauroursodeoxycholic acid (TUDCA) is a hydrophilic bile acid that is normally produced
      endogenously in humans at very low levels. TUDCA is synthesized in the liver by conjugation
      of taurine to ursodeoxycholic acid (UDCA), which is commonly used as a bile acid replacement
      therapy for the treatment of certain cholestatic syndromes.

      The main pharmacological activity of TUDCA consists in its ability in increasing the
      cholesterol solubilising activity of bile, thus transforming &quot;lithogenic&quot; bile in
      &quot;non-lithogenic&quot; or &quot;litholytic&quot; bile.

      TUDCA inhibits mitochondrial-associated apoptosis via many pathways: 1) it inhibits the
      mitochondrial permeability transition (MPT) and cytochrome C release, 2) it inhibits
      mitochondrial membrane depolarization, and 3) it antagonizes Bax translocation from the
      mitochondria and caspase activation in hepatocytes and brain. TUDCA may also ease oxidative
      stress.Study relevant TUDCA pharmacology consists in its antioxidant, antiapoptotic and
      neuroprotective activities evidenced in preclinical studies.

      Recent reports have shown that hydrophilic bile acids, such as UDCA and TUDCA, can prevent
      hepatic cytotoxicity through several mechanisms. For example, TUDCA prevents the production
      of reactive oxygen species and thus acts as an antioxidant. Additionally, TUDCA mitigates
      mitochondrial insufficiency and toxicity, and prevents apoptosis, in part, by inhibiting Bax
      translocation from cytosol to the mitochondria. In hepatocytes, this inhibition results in
      reduced mitochondrial membrane perturbation, release of cytochrome c, and activation of
      downstream caspases. TUDCA reduced cytotoxicity in neurons through similar mechanisms, as
      well as mitochondrial pathways that are independent of the permeability transition. TUDCA
      prevented striatal degeneration and ameliorated locomotor and cognitive deficits in the in
      vivo 3-nitropropionic acid (3-NP) rat model of HD. Intracellular inclusions were
      significantly reduced, and the TUDCA-treated mice showed improved locomotor and sensorimotor
      abilities.

      In addition, the antiapoptotic and cytoprotective effects of TUDCA have been tested in models
      of acute stroke. The possibility that TUDCA exerts an antiapoptotic action by ameliorating
      mitochondrial function raises the issue whether other neurological disorders, including
      Friedreich's ataxia, amyotrophic lateral sclerosis, Parkinson's disease, and Alzheimer's
      disease, can benefit by the administration of TUDCA. This drug is a candidate neuroprotective
      agent for a variety of chronic neurodegenerative conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Proportion of Responder Patients in the Two Treatment Groups According the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS)-R Slope.</measure>
    <time_frame>1 year</time_frame>
    <description>Responder patients were defined as those subjects showing an improvement of at least 15% in the ALSFRS-R slope during the treatment period as compared to the lead-in period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC) %</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36 Quality of Life Rating Scale</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Tracheostomy From Starting of Study Medication Dosing (if Appropriate)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival Time From Starting of Study Medication Dosing (if Appropriate)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALSFRS-R at Study End</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and Severity of Adverse Events, and Their Relationship to Treatment</measure>
    <time_frame>1 year</time_frame>
    <description>laboratory tests, patients' reports and the investigator's judgments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical Research Council Scores for Right and Left Muscle Groups</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>TUDCA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tauroursodeoxycholic acid di-hydrate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>excipient lactose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tauroursodeoxycholic acid (TUDCA)</intervention_name>
    <description>Oral route at the dose of 1 g b.i.d. (2 g daily) for 1 year</description>
    <arm_group_label>TUDCA</arm_group_label>
    <other_name>Ursodiol</other_name>
    <other_name>Actigall</other_name>
    <other_name>Generic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>identical placebo by oral route at the same dosing schedule</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>Oral route at the dose of 1 g b.i.d. (2 g daily) for 1 year</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Caucasian male or female out-patients;

          -  aged 18 to 75 years inclusive;

          -  diagnosis of &quot;probable&quot; or &quot;definite&quot; amyotrophic lateral sclerosis according to the
             El Escorial revised criteria (1);

          -  first symptoms of ALS by no more than 1.5 years;

          -  in treatment with steady regimen of riluzole for a minimum of 3 months before study
             entry, and desiring its continuation;

          -  FVC ≥ 75% of predicted;

          -  no conditions known to be contraindications to the use of TUDCA;

          -  written informed consent.

        Exclusion Criteria:

          -  subjects who underwent tracheostomy;

          -  subjects who underwent resection of gall bladder;

          -  subjects with signs of conduction blocks of motor nerves, sensory nerves or both on
             nerve conduction study;

          -  subjects with clinical signs of dementia;

          -  subjects with active peptic ulcer;

          -  subjects with active malignancy;

          -  subjects with bulbar onset;

          -  female subjects who are pregnant or lactating

          -  subjects who have received an experimental drug or have participated in a clinical
             trial within 3 months prior to screening

          -  employees of the investigator or study centre with direct involvement in the proposed
             study or other studies under the direction of that investigator or study centre.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alberto Albanese, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione IRCCS Istituto neurologico Carlo Besta</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto neurologico Carlo Besta</name>
      <address>
        <city>Milan</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Brooks BR, Miller RG, Swash M, Munsat TL; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000 Dec;1(5):293-9. Review.</citation>
    <PMID>11464847</PMID>
  </reference>
  <reference>
    <citation>Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, Nakanishi A. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999 Oct 31;169(1-2):13-21.</citation>
    <PMID>10540002</PMID>
  </reference>
  <reference>
    <citation>Leigh PN, Swash M, Iwasaki Y, Ludolph A, Meininger V, Miller RG, Mitsumoto H, Shaw P, Tashiro K, Van Den Berg L. Amyotrophic lateral sclerosis: a consensus viewpoint on designing and implementing a clinical trial. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Jun;5(2):84-98. Review.</citation>
    <PMID>15204010</PMID>
  </reference>
  <reference>
    <citation>Keene CD, Rodrigues CM, Eich T, Chhabra MS, Steer CJ, Low WC. Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease. Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10671-6. Epub 2002 Jul 29.</citation>
    <PMID>12149470</PMID>
  </reference>
  <reference>
    <citation>Benz C, Angermüller S, Otto G, Sauer P, Stremmel W, Stiehl A. Effect of tauroursodeoxycholic acid on bile acid-induced apoptosis in primary human hepatocytes. Eur J Clin Invest. 2000 Mar;30(3):203-9.</citation>
    <PMID>10691996</PMID>
  </reference>
  <reference>
    <citation>Schoemaker MH, Conde de la Rosa L, Buist-Homan M, Vrenken TE, Havinga R, Poelstra K, Haisma HJ, Jansen PL, Moshage H. Tauroursodeoxycholic acid protects rat hepatocytes from bile acid-induced apoptosis via activation of survival pathways. Hepatology. 2004 Jun;39(6):1563-73.</citation>
    <PMID>15185297</PMID>
  </reference>
  <reference>
    <citation>Miller SD, Greene CM, McLean C, Lawless MW, Taggart CC, O'Neill SJ, McElvaney NG. Tauroursodeoxycholic acid inhibits apoptosis induced by Z alpha-1 antitrypsin via inhibition of Bad. Hepatology. 2007 Aug;46(2):496-503.</citation>
    <PMID>17559149</PMID>
  </reference>
  <reference>
    <citation>Rodrigues CM, Solá S, Sharpe JC, Moura JJ, Steer CJ. Tauroursodeoxycholic acid prevents Bax-induced membrane perturbation and cytochrome C release in isolated mitochondria. Biochemistry. 2003 Mar 18;42(10):3070-80.</citation>
    <PMID>12627974</PMID>
  </reference>
  <reference>
    <citation>Ramalho RM, Ribeiro PS, Solá S, Castro RE, Steer CJ, Rodrigues CM. Inhibition of the E2F-1/p53/Bax pathway by tauroursodeoxycholic acid in amyloid beta-peptide-induced apoptosis of PC12 cells. J Neurochem. 2004 Aug;90(3):567-75.</citation>
    <PMID>15255934</PMID>
  </reference>
  <reference>
    <citation>Rodrigues CM, Sola S, Nan Z, Castro RE, Ribeiro PS, Low WC, Steer CJ. Tauroursodeoxycholic acid reduces apoptosis and protects against neurological injury after acute hemorrhagic stroke in rats. Proc Natl Acad Sci U S A. 2003 May 13;100(10):6087-92. Epub 2003 Apr 29.</citation>
    <PMID>12721362</PMID>
  </reference>
  <reference>
    <citation>Ramalho RM, Borralho PM, Castro RE, Solá S, Steer CJ, Rodrigues CM. Tauroursodeoxycholic acid modulates p53-mediated apoptosis in Alzheimer's disease mutant neuroblastoma cells. J Neurochem. 2006 Sep;98(5):1610-8.</citation>
    <PMID>16923170</PMID>
  </reference>
  <reference>
    <citation>Ved R, Saha S, Westlund B, Perier C, Burnam L, Sluder A, Hoener M, Rodrigues CM, Alfonso A, Steer C, Liu L, Przedborski S, Wolozin B. Similar patterns of mitochondrial vulnerability and rescue induced by genetic modification of alpha-synuclein, parkin, and DJ-1 in Caenorhabditis elegans. J Biol Chem. 2005 Dec 30;280(52):42655-42668. doi: 10.1074/jbc.M505910200. Epub 2005 Oct 19.</citation>
    <PMID>16239214</PMID>
  </reference>
  <reference>
    <citation>Solá S, Castro RE, Laires PA, Steer CJ, Rodrigues CM. Tauroursodeoxycholic acid prevents amyloid-beta peptide-induced neuronal death via a phosphatidylinositol 3-kinase-dependent signaling pathway. Mol Med. 2003 Sep-Dec;9(9-12):226-34.</citation>
    <PMID>15208744</PMID>
  </reference>
  <reference>
    <citation>Rudolph G, Kloeters-Plachky P, Sauer P, Stiehl A. Intestinal absorption and biliary secretion of ursodeoxycholic acid and its taurine conjugate. Eur J Clin Invest. 2002 Aug;32(8):575-80.</citation>
    <PMID>12190957</PMID>
  </reference>
  <reference>
    <citation>Keene CD, Rodrigues CM, Eich T, Linehan-Stieers C, Abt A, Kren BT, Steer CJ, Low WC. A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease. Exp Neurol. 2001 Oct;171(2):351-60.</citation>
    <PMID>11573988</PMID>
  </reference>
  <reference>
    <citation>Castro RE, Solá S, Ramalho RM, Steer CJ, Rodrigues CM. The bile acid tauroursodeoxycholic acid modulates phosphorylation and translocation of bad via phosphatidylinositol 3-kinase in glutamate-induced apoptosis of rat cortical neurons. J Pharmacol Exp Ther. 2004 Nov;311(2):845-52. Epub 2004 Jun 9.</citation>
    <PMID>15190125</PMID>
  </reference>
  <reference>
    <citation>Ince PG, Tomkins J, Slade JY, Thatcher NM, Shaw PJ. Amyotrophic lateral sclerosis associated with genetic abnormalities in the gene encoding Cu/Zn superoxide dismutase: molecular pathology of five new cases, and comparison with previous reports and 73 sporadic cases of ALS. J Neuropathol Exp Neurol. 1998 Oct;57(10):895-904.</citation>
    <PMID>9786240</PMID>
  </reference>
  <reference>
    <citation>Chaudhuri KR, Crump S, al-Sarraj S, Anderson V, Cavanagh J, Leigh PN. The validation of El Escorial criteria for the diagnosis of amyotrophic lateral sclerosis: a clinicopathological study. J Neurol Sci. 1995 May;129 Suppl:11-2.</citation>
    <PMID>7595600</PMID>
  </reference>
  <reference>
    <citation>Turner MR, Bakker M, Sham P, Shaw CE, Leigh PN, Al-Chalabi A. Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2002 Mar;3(1):15-21.</citation>
    <PMID>12061944</PMID>
  </reference>
  <reference>
    <citation>Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci. 2001 Nov;2(11):806-19. Review.</citation>
    <PMID>11715057</PMID>
  </reference>
  <reference>
    <citation>Shaw CE, al-Chalabi A, Leigh N. Progress in the pathogenesis of amyotrophic lateral sclerosis. Curr Neurol Neurosci Rep. 2001 Jan;1(1):69-76. Review.</citation>
    <PMID>11898502</PMID>
  </reference>
  <reference>
    <citation>Heath PR, Shaw PJ. Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis. Muscle Nerve. 2002 Oct;26(4):438-58. Review.</citation>
    <PMID>12362409</PMID>
  </reference>
  <reference>
    <citation>Sathasivam S, Ince PG, Shaw PJ. Apoptosis in amyotrophic lateral sclerosis: a review of the evidence. Neuropathol Appl Neurobiol. 2001 Aug;27(4):257-74. Review.</citation>
    <PMID>11532157</PMID>
  </reference>
  <reference>
    <citation>Rizzardini M, Lupi M, Bernasconi S, Mangolini A, Cantoni L. Mitochondrial dysfunction and death in motor neurons exposed to the glutathione-depleting agent ethacrynic acid. J Neurol Sci. 2003 Mar 15;207(1-2):51-8.</citation>
    <PMID>12614931</PMID>
  </reference>
  <reference>
    <citation>Robertson J, Kriz J, Nguyen MD, Julien JP. Pathways to motor neuron degeneration in transgenic mouse models. Biochimie. 2002 Nov;84(11):1151-60. Review.</citation>
    <PMID>12595144</PMID>
  </reference>
  <reference>
    <citation>Rosen DR. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993 Jul 22;364(6435):362.</citation>
    <PMID>8332197</PMID>
  </reference>
  <reference>
    <citation>Shaw CE, Enayat ZE, Chioza BA, Al-Chalabi A, Radunovic A, Powell JF, Leigh PN. Mutations in all five exons of SOD-1 may cause ALS. Ann Neurol. 1998 Mar;43(3):390-4.</citation>
    <PMID>9506558</PMID>
  </reference>
  <reference>
    <citation>Yang Y, Hentati A, Deng HX, Dabbagh O, Sasaki T, Hirano M, Hung WY, Ouahchi K, Yan J, Azim AC, Cole N, Gascon G, Yagmour A, Ben-Hamida M, Pericak-Vance M, Hentati F, Siddique T. The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat Genet. 2001 Oct;29(2):160-5.</citation>
    <PMID>11586297</PMID>
  </reference>
  <reference>
    <citation>Puls I, Jonnakuty C, LaMonte BH, Holzbaur EL, Tokito M, Mann E, Floeter MK, Bidus K, Drayna D, Oh SJ, Brown RH Jr, Ludlow CL, Fischbeck KH. Mutant dynactin in motor neuron disease. Nat Genet. 2003 Apr;33(4):455-6. Epub 2003 Mar 10.</citation>
    <PMID>12627231</PMID>
  </reference>
  <reference>
    <citation>Al-Chalabi A, Andersen PM, Nilsson P, Chioza B, Andersson JL, Russ C, Shaw CE, Powell JF, Leigh PN. Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis. Hum Mol Genet. 1999 Feb;8(2):157-64.</citation>
    <PMID>9931323</PMID>
  </reference>
  <reference>
    <citation>Friedlander RM. Apoptosis and caspases in neurodegenerative diseases. N Engl J Med. 2003 Apr 3;348(14):1365-75. Review.</citation>
    <PMID>12672865</PMID>
  </reference>
  <reference>
    <citation>Waldmeier PC. Prospects for antiapoptotic drug therapy of neurodegenerative diseases. Prog Neuropsychopharmacol Biol Psychiatry. 2003 Apr;27(2):303-21. Review.</citation>
    <PMID>12657369</PMID>
  </reference>
  <reference>
    <citation>Worms PM. The epidemiology of motor neuron diseases: a review of recent studies. J Neurol Sci. 2001 Oct 15;191(1-2):3-9. Review.</citation>
    <PMID>11676986</PMID>
  </reference>
  <reference>
    <citation>Mandrioli J, Faglioni P, Merelli E, Sola P. The epidemiology of ALS in Modena, Italy. Neurology. 2003 Feb 25;60(4):683-9.</citation>
    <PMID>12601112</PMID>
  </reference>
  <reference>
    <citation>Emery AE, Holloway S. Familial motor neuron diseases. Adv Neurol. 1982;36:139-47.</citation>
    <PMID>7180680</PMID>
  </reference>
  <reference>
    <citation>Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994 Mar 3;330(9):585-91.</citation>
    <PMID>8302340</PMID>
  </reference>
  <reference>
    <citation>Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet. 1996 May 25;347(9013):1425-31.</citation>
    <PMID>8676624</PMID>
  </reference>
  <reference>
    <citation>Orrell RW, Lane RJ, Ross M. Antioxidant treatment for amyotrophic lateral sclerosis / motor neuron disease. Cochrane Database Syst Rev. 2005 Jan 25;(1):CD002829. Review. Update in: Cochrane Database Syst Rev. 2007;(1):CD002829.</citation>
    <PMID>15674899</PMID>
  </reference>
  <reference>
    <citation>Moore DH 2nd, Miller RG. Improving efficiency of ALS clinical trials using lead-in designs. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Sep;5 Suppl 1:57-60.</citation>
    <PMID>15512875</PMID>
  </reference>
  <reference>
    <citation>Miller RG, Munsat TL, Swash M, Brooks BR. Consensus guidelines for the design and implementation of clinical trials in ALS. World Federation of Neurology committee on Research. J Neurol Sci. 1999 Oct 31;169(1-2):2-12. Review.</citation>
    <PMID>10540001</PMID>
  </reference>
  <reference>
    <citation>Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med. 2001 May 31;344(22):1688-700. Review.</citation>
    <PMID>11386269</PMID>
  </reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2009</study_first_submitted>
  <study_first_submitted_qc>April 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2009</study_first_posted>
  <results_first_submitted>October 31, 2014</results_first_submitted>
  <results_first_submitted_qc>November 19, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 26, 2014</results_first_posted>
  <last_update_submitted>November 19, 2014</last_update_submitted>
  <last_update_submitted_qc>November 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta</investigator_affiliation>
    <investigator_full_name>Alberto Albanese</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>ALS</keyword>
  <keyword>Therapy</keyword>
  <keyword>Tauroursodeoxycholic acid</keyword>
  <keyword>TUDCA</keyword>
  <keyword>antioxidant</keyword>
  <keyword>antiapoptotic drug</keyword>
  <keyword>neuroprotective drug</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tauroursodeoxycholic acid</mesh_term>
    <mesh_term>Taurochenodeoxycholic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment is started on eightth of october 2009, in medical clinics (Besta Institute in Milan, University II department of Neurology of Naples, University of Palermo department of Neurology).</recruitment_details>
      <pre_assignment_details>34 patients enrolled, 5 of whom dropped out during the lead in phase.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TUDCA</title>
          <description>tauroursodeoxycholic acid di-hydrate
tauroursodeoxycholic acid (TUDCA): Oral route at the dose of 1 g b.i.d. (2 g daily) for 1 year</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>excipient lactose
Placebo: identical placebo by oral route at the same dosing schedule composed of excipient lactose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TUDCA</title>
          <description>tauroursodeoxycholic acid di-hydrate
tauroursodeoxycholic acid (TUDCA): Oral route at the dose of 1 g b.i.d. (2 g daily) for 1 year</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>excipient lactose
Placebo: identical placebo by oral route at the same dosing schedule</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.0" spread="12.2"/>
                    <measurement group_id="B2" value="58.2" spread="12.9"/>
                    <measurement group_id="B3" value="56.1" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Proportion of Responder Patients in the Two Treatment Groups According the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS)-R Slope.</title>
        <description>Responder patients were defined as those subjects showing an improvement of at least 15% in the ALSFRS-R slope during the treatment period as compared to the lead-in period.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TUDCA</title>
            <description>tauroursodeoxycholic acid di-hydrate
tauroursodeoxycholic acid (TUDCA): Oral route at the dose of 1 g b.i.d. (2 g daily) for 1 year</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>excipient lactose
Placebo: identical placebo by oral route at the same dosing schedule composed of excipient lactose</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Responder Patients in the Two Treatment Groups According the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS)-R Slope.</title>
          <description>Responder patients were defined as those subjects showing an improvement of at least 15% in the ALSFRS-R slope during the treatment period as compared to the lead-in period.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Vital Capacity (FVC) %</title>
        <time_frame>1 year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SF-36 Quality of Life Rating Scale</title>
        <time_frame>1 year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Tracheostomy From Starting of Study Medication Dosing (if Appropriate)</title>
        <time_frame>1 year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival Time From Starting of Study Medication Dosing (if Appropriate)</title>
        <time_frame>1 year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ALSFRS-R at Study End</title>
        <time_frame>1 year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence and Severity of Adverse Events, and Their Relationship to Treatment</title>
        <description>laboratory tests, patients’ reports and the investigator’s judgments</description>
        <time_frame>1 year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Medical Research Council Scores for Right and Left Muscle Groups</title>
        <time_frame>1 year</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>TUDCA</title>
          <description>tauroursodeoxycholic acid di-hydrate
tauroursodeoxycholic acid (TUDCA): Oral route at the dose of 1 g b.i.d. (2 g daily) for 1 year</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>excipient lactose
Placebo: identical placebo by oral route at the same dosing schedule composed of excipient lactose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alberto Albanese</name_or_title>
      <organization>Fondazione Istituto Neurologico Carlo Besta</organization>
      <phone>+39 02 2392 4552</phone>
      <email>alberto.albanese@unicatt.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

